Skip to main content

Table 2 Changes in primary and secondary efficacy variables: days 28 and 56

From: Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia – short term evaluation of safety and tolerability

  Amount of change
Parameter Placebo (n = 16) 40 mg PC-SOD (n = 17) 80 mg PC-SOD (n = 17)
Day 28    
FVC, % 2.068 ± 6.539 -2.567 ± 12.175 2.927 ± 11.822
LDH, % 0.0 ± 11.3 -0.1 ± 22.1 -12.4 ± 11.0*
SP-A, % -1.9 ± 20.8 -10.9 ± 22.3 -21.2 ± 16.9†
SP-D, % -5.1 ± 24.4 -10.9 ± 31.5 -8.6 ± 45.6
KL-6, % -4.7 ± 14.4 -7.3 ± 16.8 -8.0 ± 18.5
Borg scale -0.19 ± 0.77 0.26 ± 1.94 0.15 ± 1.41
Day 56    
FVC, % 1.127 ± 7.951 -1.993 ± 13.517 0.606 ± 13.716
LDH, % 1.5 ± 14.4 3.6 ± 24.8 2.4 ± 19.3
SP-A, % 3.1 ± 18.1 -1.3 ± 23.8 3.4 ± 19.9
SP-D, % 7.6 ± 41.4 -7.8 ± 35.5 10.9 ± 66.1
KL-6, % -2.7 ± 17.9 -2.8 ± 18.6 -0.7 ± 21.1
Borg scale -0.06 ± 1.08 0.06 ± 1.08 0.97 ± 2.24
  1. Mean ± SD. *P < 0.05 vs. placebo, † P < 0.01 vs. placebo.
  2. Definition of abbreviations: PC-SOD = lecithinized superoxide dismutase; FVC = forced vital capacity; LDH = lactate dehydrogenase; SP-A = surfactant protein-A; SP-D = surfactant protein-D; KL-6 = Krebs von den Lungen-6.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us

\